Clinical Trials Logo

Advanced Synovial Sarcoma clinical trials

View clinical trials related to Advanced Synovial Sarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04965753 Terminated - Clinical trials for Advanced Synovial Sarcoma

FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Start date: August 17, 2021
Phase: Phase 1
Study type: Interventional

This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-609 given intravenously in subjects with advanced synovial sarcoma or advanced SMARCB1-loss tumors.

NCT ID: NCT03670069 Terminated - Clinical trials for Metastatic Soft Tissue Sarcoma

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Start date: September 30, 2019
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02650986 Active, not recruiting - Metastatic Melanoma Clinical Trials

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Start date: July 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens 1 (NY-ESO-1) gene that have spread to other places in the body (advanced). A T cell is a type of immune cell that can recognize and kill abnormal cells of the body. Placing a modified gene for NY-ESO-1 into the patients' T cells in the laboratory and then giving them back to the patient may help the body build an immune response to kill tumor cells that express NY-ESO-1. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving gene-modified T cells with or without decitabine works better in treating patients with malignancies expressing NY-ESO-1.